Denteric

Denteric is developing precision immunotherapies for chronic Porphyromonas gingivalis infections.

Denteric is developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis) and related species. In so doing, its primary goal is to provide options to treat and prevent severe periodontal disease and its complications, a condition which affects approximately 1 in 10 people globally. In time, it is also possible that this approach will have relevance in additional medical conditions which are associated with P gingivalis and related species.

https://www.denteric.com/

Brandon Capital is aware of scammers impersonating us - offering jobs and asking for bank details. We do not offer employment or ask for banking details via SMS, websites or phone calls. Do not provide any details and report to the relevant authorities in your location.